Stephen Bloch

Having been an entrepreneur and practicing physician, Dr. Stephen Bloch knows first hand the challenges of building successful healthcare companies. He draws on his medical, academic and research experience, to make winning investments in biopharmaceuticals, medical devices and diagnostics and healthcare infrastructure.  Stephen led Canaan’s investment in Amicus Therapeutics (FOLD), a clinical-stage biopharmaceutical company developing next-generation oral therapies for the management of genetic diseases such as Gaucher’s and Parkinson’s Disease. Amicus achieved the largest pre-money IPO valuation for an early clinical biotech company since 2000.

Previous to joining Canaan in 2002, Stephen founded Radiology Management Sciences (RMS), a risk manager of diagnostic imaging services, where he was CEO for six years. Before founding RMS, Stephen helped start and served as medical director of Omnisonics Medical Technologies, which is commercializing novel ultrasonic devices to treat vascular occlusive disease. He also co-founded TeleRad, a teleradiology services company.

In addition to his operational experience, Stephen worked as a strategic consultant with global consultancy Arthur D. Little focused on pharmaceuticals and medical devices.  Stephen started his career as a practicing radiologist. In addition to his board role at Amicus Therapeutics and at Omnisonics, Stephen is a director of Advanced Biohealing, which develops and markets regenerative wound healing therapies; Marinus Pharmaceuticals, a leader in development of drugs to treat serious neurological disorders and Viacor, a pioneer of minimally invasive cardiac valve repair.

Stephen received his medical training at Massachusetts General Hospital/Harvard Medical School and Lenox Hill Hospital/Cornell Medical School. He earned his medical degree from the University of Rochester, a MA in the history of science and public policy from Harvard University and an AB degree from Dartmouth College. Stephen was honored as a Ewing Marion Kauffman Fellow in 2002, an educational program that develops future leaders of the global venture capital industry.

Print Photo [tif, 4.5MB]
Web Photo [jpg, 108KB]

CONNECTICUT LOCAL TIME: